EB-2 NIWBiotech and pharmaIndividualDecided June 2026Dismissed
Outcome: Dismissed
JUN112026_02B5203
Merit and national importanceNot metWell positionedNot reached / not discussedBalance favors a waiverNot reached / not discussed
Our summary
A biomedical scientist and biotechnology executive with experience in molecular biology and clinical diagnostics proposed to establish a venture consulting practice for early-stage biotech companies. The AAO dismissed the appeal because the petitioner failed to demonstrate the proposed endeavor's national importance; the record showed only individualized client services without broader field-wide impact.
Official PDF
Official PDF ↗Published by USCIS. The summary is ours, in our own words; the decision text is on uscis.gov.
No criterion in the table was found met in this decision.
What was missing
- Merit and national importance · Proposed venture consulting practice lacks demonstrated national importance; impact limited to individual clients without broader field implications.
Criteria
| Criterion | Reading | Why |
|---|---|---|
 Merit and national importance | Not met | Proposed venture consulting practice lacks demonstrated national importance; impact limited to individual clients without broader field implications. |
 Well positioned | Not reached / not discussed | First prong failed; second prong not reached per Bagamasbad doctrine. |
 Balance favors a waiver | Not reached / not discussed | First prong failed; third prong not reached per Bagamasbad doctrine. |
A published decision describes one case. It is not legal advice and not a prediction for yours.